Abstract
Autoantibodies and lupus-like syndromes can develop following the use of certain medications; however, although many patients develop autoantibodies, only a minority develop clinical features. Although these autoantibodies primarily consist of antinuclear and antihistone antibodies, additional types of antibody, such as antineutrophil cytoplasmic antibodies and anti-double-stranded DNA antibodies, have been reported in association with minocycline and tumor necrosis factor inhibitor therapy. Clinical features of drug-related lupus usually consist of constitutional symptoms, arthralgias, arthritis, myalgias and serositis, although cutaneous manifestations have been reported in association with the use of tumor necrosis factor inhibitors. Typically, clinical features resolve with discontinuation of the medication, although antibodies can persist for months or years. Arthralgias and inflammatory arthritis have also been reported in association with the use of aromatase inhibitors and other biologic agents such as interleukins and interferons.
Key Points
-
Autoantibodies are associated with the use of certain medications
-
Although many patients develop autoantibodies, only a minority develop autoimmune-like diseases
-
The development of autoantibodies alone is not sufficient reason to discontinue the medication
-
Patients treated with medications such as tumor necrosis factor inhibitors and minocycline who develop an apparent 'flare' of the disease should be evaluated for the possibility of drug-related lupus
-
Rechallenge with minocycline might be useful in order to confirm a diagnosis of minocycline-related lupus
-
Clinical trial data indicate that patients who receive aromatase inhibitors can develop arthralgias and arthritis, although no data regarding the development of autoantibodies have been reported
-
Patients with pre-existing thyroid autoantibodies are more likely to develop autoimmune thyroid disease when treated with interferon-α than patients with no pre-existing condition
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mongey AB et al. (1992) Serologic evaluation of patients receiving procainamide. Arthritis Rheum 35: 219–223
Burlingame RW and Rubin RL (1991) Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 88: 680–690
Cohen MG et al. (1988) Two distinct quinidine-induced rheumatic syndromes. Ann Intern Med 108: 369–371
Rubin RL et al. (1992) Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 90: 165–173
Bray VJ et al. (1994) Antihistone autoantibody profile in sulfasalazine induced lupus. J Rheumatol 21: 2157–2158
Sherer Y et al. (2004) Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34: 501–537
Elkayam O et al. (1998) Clinical and immunological study of 7 patients with minocycline-induced autoimmune phenomena. Am J Med 105: 484–487
Tournigand C et al. (1999) Minocycline-induced clinical and biological lupus-like disease. Lupus 8: 773–774
Gough A et al. (1996) Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312: 169–172
Lawson TM et al. (2001) Minocycline induced lupus: clinical features and response to rechallenge. Rheumatology (Oxford) 40: 329–335
Gordon MM and Porter D (2001) Minocycline related lupus: case series in the West of Scotland. J Rheumatol 28: 1004–1006
Elkayam O et al. (1996) Minocycline induced arthritis associated with fever, livedo reticularis and pANCA. Ann Rheum Dis 55: 769–771
Knowles SR et al. (1996) Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 132: 934–939
Knights S et al. (1998) Minocycline-induced arthritis. Clin Exp Rheumatol 16: 587–590
Sturkenboom MC et al. (1999) Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 159: 493–497
Dunphy J et al. (2000) Anti-neutrophil cytoplasmic antibodies and HLA class II alleles in minocyline-induced lupus like-syndrome. Br J Dermatol 142: 461–467
Gunnarrson I et al. (2000) Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment—the role of IL-10 and HLA. Rheumatology (Oxford) 39: 886–893
Gordon M-M et al. (1999) Does sulphasalazine cause drug-induced lupus erythematosus? No effect evident in a prospective randomized trial of 200 rheumatoid patients treated with sulfasalazine or auranofin over five years. Ann Rheum Dis 58: 288–290
Noël B (2007) Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 21: 17–24
Kaur H et al. (2001) Simvastatin-induced lupus erythematosus. Presented at the ACP-ASIM Ohio Chapter Scientific Meeting: 2001 October 12–13, Cleveland, OH
Obermoser GE et al. (2001) Lupus-like syndrome associated with Atorvastatin. Lupus 10: S121
Raggatt LJ and Partridge NC (2002) HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 62: 2185–2191
Baum M et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359: 2131–2139
Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802
Coombes RC et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081–1092
Donnellan PP et al. (2001) Aromatase inhibitors and arthralgia [letter]. J Clin Oncol 19: 2767
Bonneterre J et al. (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748–3757
Dombernowsky P et al. (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461
Markham A and Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59: 1341–1359
Vermeire S et al. (2003) Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125: 32–39
Charles PJ et al. (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43: 2383–2390
Elkayam O et al. (2005) Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38: 155–160
De Rycke L et al. (2003) Antinuclear antibodies following infliximab treatment inpatients with rheumatoid arthritis or spondyloarthropathy. Arthritis Rheum 48: 1015–1023
Haraoui B et al. (2006) Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatology 18: 96–100
Shakoor N et al. (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359: 579–580
De Rycke L et al. (2005) Infliximab, but not etanercept, induced IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 52: 2192–2201
Eriksson C et al. (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64: 403–407
DeBandt M (2006) Lessons for lupus from tumor necrosis factor blockade. Lupus 15: 762–767
Jonsdottir T et al. (2004) Treatment with tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 63: 1075–1078
Cairns AP et al. (1999) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61: 1031–1032
Brion PH et al. (1999) Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 131: 634
DeBandt M et al. (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22: 56–61
Mohan AK et al. (2002) Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet 360: 646
Mor A et al. (2005) Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 32: 740–743
Stokes et al. (2005) Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 20: 1400–1406
Mohan N et al. (2004) Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 31: 1955–1958
De Bandt M et al. (2005) Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7: R545–551
Ramos-Casals M et al. (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86: 242–251
Schiff MH et al. (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65: 889–894
Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64 (Suppl 4): iv18–23
Rönnblom LE et al. (1991) Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 115: 178–183
Mayet WJ et al. (1989) Treatment of chronic type B hepatitis with recombinant alpha-interferon induced autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 10: 24–28
Atkins MB et al. (1988) Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 1557–1563
Gisslinger H et al. (1992) Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha. Clin Exp Immunol 90: 363–367
Conlon KC et al. (1990) Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237–2242
Flores A et al. (1994) Systemic lupus erythematosus following interferon therapy. Br J Rheumatol 33: 787–792
Obermoser G et al. (2001) Lupus-like syndrome following interferon therapy in a patient with chronic myelogenous leukemia. Lupus 10: S121
Koon H and Atkins M (2006) Autoimmunity and immunotherapy for cancer. N Engl J Med 354: 758–760
Massarotti EM et al. (1992) Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 92: 693–697
Gogas H et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354: 709–718
Lahita RG (Ed.; 1999) Systemic Lupus Erythematosus, edn 3. New York, NY: Academic Press
Acknowledgements
Charles P Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mongey, AB., Hess, E. Drug Insight: autoimmune effects of medications—what's new?. Nat Rev Rheumatol 4, 136–144 (2008). https://doi.org/10.1038/ncprheum0708
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0708
This article is cited by
-
A Spotlight on Drug-Induced Vasculitis
Current Rheumatology Reports (2022)
-
Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α
International Archives of Medicine (2012)
-
The safety and side effects of monoclonal antibodies
Nature Reviews Drug Discovery (2010)
-
Biologics
Der Hautarzt (2010)